The DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures
Open accessAbstract
Disease overview: Chronic lymphocytic leukemia (CLL) is one of the most frequent types of leukemia. It typically occurs in elderly patients and has a highly variable clinical course. Leukemic transformation is initiated by specific genomic alterations that interfere with the regulation of proliferation and of apoptosis in clonal B‐cells. Diagnosis: The diagnosis is established by blood counts, blood smears, and immunophenotyping of circulating B‐lymphocytes, which identify a clonal B‐cell population carrying the CD5 antigen as well as typical B‐cell markers. Prognosis and staging: The clinical staging systems provide prognostic information by using the results of physical examination and blood counts. Various biological and genetic markers provide additional prognostic information. Deletions of the short arm of chromosome 17 (del[17p]) and/or mutations of the TP53 gene predict resistance to chemoimmunotherapy and a shorter time to progression with most targeted therapies. The CLL international prognostic index integrates genetic, biological, and clinical variables to identify distinct risk groups of patients with CLL. Therapy: Only patients with active or symptomatic disease or with advanced Binet or Rai stages require therapy. When treatment is indicated, several therapeutic options exist: a combination of the B‐cell lymphoma 2 (BCL2) inhibitor venetoclax with obinutuzumab, monotherapy with inhibitors of Bruton tyrosine kinase (BTK) such as ibrutinib and acalabrutinib, or chemoimmunotherapy. At relapse, the initial treatment may be repeated, if the treatment‐free interval exceeds 3 years. If the disease relapses earlier, therapy should be changed using an alternative regimen. Patients with a del(17p) or TP53 mutation are usually resistant to chemotherapy and should, therefore, be treated with targeted agents. Future challenges: Combinations of targeted agents are now being investigated to create efficient, potentially curative therapies of CLL with fixed duration. One of the most relevant questions currently addressed in clinical trials is the comparison of monotherapies with BTK inhibitors with fixed duration combination therapies. Moreover, the optimal sequencing of targeted therapies remains to be determined. Alternative therapies are needed for patients with BTK and BCL2 inhibitor double‐refractory disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092
Calin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., Aldler, H., Rattan, S., Keating, M., Rai, K., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242606799 · Cited by 5,111
Hossfeld, D. K. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf146 · Cited by 4,625
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia
Döhner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Kröber, A., Bullinger, L., Döhner, K., Bentz, M., & Lichter, P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012283432602 · Cited by 3,318
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
Clinical staging of chronic lymphocytic leukemia
Rai, K., Sawitsky, A., Cronkite, E., Chanana, A., Levy, R., & Pasternack, B. (1975) · Blood · doi:10.1182/blood.v46.2.219.219 · Cited by 2,784
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,900
Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Grünhagen, U., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61381-5 · Cited by 1,888
Self-citationBinet, J. L., Auquier, A., Dighiero, G., Chastang, C., Piguet, H., Goasguen, J., Vaugier, G., Potron, G., Colona, P., Oberling, F., et al. (1981) · Cancer · doi:10.1002/1097-0142(19810701)48:1<198::aid-cncr2820480131>3.0.co;2-v · Cited by 1,778
Tsujimoto, Y., Finger, L. R., Yunis, J., Nowell, P. C., & Croce, C. M. (1984) · Science · doi:10.1126/science.6093263 · Cited by 1,769
Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M., Montserrat, E., Chiorazzi, N., et al. (2018) · Blood · doi:10.1182/blood-2017-09-806398 · Cited by 1,740
Self-citationIdelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315226 · Cited by 1,710
Self-citationBCL-2 FAMILY: Regulators of Cell Death
Chao, D. T., & Korsmeyer, S. J. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.395 · Cited by 1,685
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
Byrd, J. C., Brown, J. R., O'Brien, S., Barrientos, J. C., Kay, N. E., Reddy, N. M., Coutre, S., Tam, C. S., Mulligan, S. P., Jaeger, U., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400376 · Cited by 1,639
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
Burger, J. A., Tedeschi, A., Barr, P. M., Robak, T., Owen, C., Ghia, P., Bairey, O., Hillmen, P., Bartlett, N. L., Li, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509388 · Cited by 1,583
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Goede, V., Fischer, K., Busch, R., Engelke, A., Eichhorst, B., Wendtner, C. M., Chagorova, T., de la Serna, J., Dilhuydy, M.-S., Illmer, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313984 · Cited by 1,518
Self-citationWhole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
Puente, X. S., Pinyol, M., Quesada, V., Conde, L., Ordóñez, G. R., Villamor, N., Escaramis, G., Jares, P., Beà, S., González-Díaz, M., et al. (2011) · Nature · doi:10.1038/nature10113 · Cited by 1,514
Fischer, K., Bahlo, J., Fink, A. M., Goede, V., Herling, C. D., Cramer, P., Langerbeins, P., von Tresckow, J., Engelke, A., Maurer, C., et al. (2016) · Blood · doi:10.1182/blood-2015-06-651125 · Cited by 1,299
Self-citationChiorazzi, N., Rai, K. R., & Ferrarini, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041720 · Cited by 1,296
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Woyach, J. A., Furman, R. R., Liu, T.-M., Ozer, H. G., Zapatka, M., Ruppert, A. S., Xue, L., Li, D. H.-H., Steggerda, S. M., Versele, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400029 · Cited by 1,275 · cited 1×
“ibrutinib in five patients and three distinct mutations in PLCgamma2 in two patients.(117) The C481S mutation of BTK results in a protein that is only reversibly inhibited by ibrutinib.”
BackgroundAdvani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128 · cited 1×
“6 months.(112) The most relevant treatment-related side effects were viral infections.”
BackgroundMutations driving CLL and their evolution in progression and relapse
Landau, D. A., Tausch, E., Taylor-Weiner, A. N., Stewart, C., Reiter, J. G., Bahlo, J., Kluth, S., Bozic, I., Lawrence, M., Böttcher, S., et al. (2015) · Nature · doi:10.1038/nature15395 · Cited by 1,068
Self-citationFludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia
Rai, K. R., Peterson, B. L., Appelbaum, F. R., Kolitz, J., Elias, L., Shepherd, L., Hines, J., Threatte, G. A., Larson, R. A., Cheson, B. D., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012143432402 · Cited by 1,001
Quesada, V., Conde, L., Villamor, N., Ordóñez, G. R., Jares, P., Bassaganyas, L., Ramsay, A. J., Beà, S., Pinyol, M., Martínez-Trillos, A., et al. (2012) · Nature Genetics · doi:10.1038/ng.1032 · Cited by 996
Comorbidity and functional status are independent in older cancer patients.
Extermann, M., Overcash, J., Lyman, G. H., Parr, J., & Balducci, L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.4.1582 · Cited by 984
Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C., Nopora, A., van Puijenbroek, E., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225979 · Cited by 981
Sant, M., Allemani, C., Tereanu, C., De Angelis, R., Capocaccia, R., Visser, O., Marcos-Gragera, R., Maynadié, M., Simonetti, A., Lutz, J.-M., et al. (2010) · Blood · doi:10.1182/blood-2010-05-282632 · Cited by 977
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
Woyach, J. A., Ruppert, A. S., Heerema, N. A., Zhao, W., Booth, A. M., Ding, W., Bartlett, N. L., Brander, D. M., Barr, P. M., Rogers, K. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1812836 · Cited by 962
Keating, M. J., Flinn, I., Jain, V., Binet, J.-L., Hillmen, P., Byrd, J., Albitar, M., Brettman, L., Santabarbara, P., Wacker, B., et al. (2002) · Blood · doi:10.1182/blood.v99.10.3554 · Cited by 948
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Seymour, J. F., Kipps, T. J., Eichhorst, B., Hillmen, P., D’Rozario, J., Assouline, S., Owen, C., Gerecitano, J., Robak, T., De la Serna, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713976 · Cited by 940
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Harrington, B., O’Brien, S., Jones, J. A., Schuh, A., Devereux, S., Chaves, J., Wierda, W. G., Awan, F. T., Brown, J. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509981 · Cited by 897
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
Fischer, K., Al-Sawaf, O., Bahlo, J., Fink, A.-M., Tandon, M., Dixon, M., Robrecht, S., Warburton, S., Humphrey, K., Samoylova, O., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1815281 · Cited by 873
Self-citationKlein, U., Lia, M., Crespo, M., Siegel, R., Shen, Q., Mo, T., Ambesi-Impiombato, A., Califano, A., Migliazza, A., Bhagat, G., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.019 · Cited by 848
Non-coding recurrent mutations in chronic lymphocytic leukaemia
Puente, X. S., Beà, S., Valdés-Mas, R., Villamor, N., Gutiérrez-Abril, J., Martín-Subero, J. I., Munar, M., Rubio-Pérez, C., Jares, P., Aymerich, M., et al. (2015) · Nature · doi:10.1038/nature14666 · Cited by 829
PI3K in lymphocyte development, differentiation and activation
Okkenhaug, K., & Vanhaesebroeck, B. (2003) · Nature Reviews Immunology · doi:10.1038/nri1056 · Cited by 810
Herman, S. E. M., Gordon, A. L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., Flynn, J., Jones, J., Blum, K. A., Buggy, J. J., et al. (2011) · Blood · doi:10.1182/blood-2011-01-328484 · Cited by 807
Stilgenbauer, S., Eichhorst, B., Schetelig, J., Coutre, S., Seymour, J. F., Munir, T., Puvvada, S. D., Wendtner, C.-M., Roberts, A. W., Jurczak, W., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30019-5 · Cited by 805
Self-citationMatutes, E., Owusu-Ankomah, K. A., Morilla, R. M., García Marco, J., Houlihan, A., Que, T., & Catovsky, D. (1994) · PubMed · Cited by 779
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
Shanafelt, T. D., Wang, X. V., Kay, N. E., Hanson, C. A., O’Brien, S., Barrientos, J., Jelinek, D. F., Braggio, E., Leis, J. F., Zhang, C. C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817073 · Cited by 749
Tam, C. S., O'Brien, S., Wierda, W., Kantarjian, H., Wen, S., Do, K.-A., Thomas, D. A., Cortes, J., Lerner, S., & Keating, M. J. (2008) · Blood · doi:10.1182/blood-2008-02-140582 · Cited by 693
Catovsky, D., Richards, S., Matutes, E., Oscier, D., Dyer, M., Bezares, R., Pettitt, A., Hamblin, T., Milligan, D., Child, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61125-8 · Cited by 677
(2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30029-8 · Cited by 672
Byrd, J. C., Hillmen, P., Ghia, P., Kater, A. P., Chanan-Khan, A., Furman, R. R., O'Brien, S., Yenerel, M. N., Illés, A., Kay, N., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01210 · Cited by 669
Turtle, C. J., Hay, K. A., Hanafi, L.-A., Li, D., Cherian, S., Chen, X., Wood, B., Lozanski, A., Byrd, J. C., Heimfeld, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.8519 · Cited by 662
Sharman, J. P., Egyed, M., Jurczak, W., Skarbnik, A., Pagel, J. M., Flinn, I. W., Kamdar, M., Munir, T., Walewska, R., Corbett, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30262-2 · Cited by 631
Eichhorst, B., Fink, A.-M., Bahlo, J., Busch, R., Kovacs, G., Maurer, C., Lange, E., Köppler, H., Kiehl, M., Sökler, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30051-1 · Cited by 627
Self-citationMonoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia
Rawstron, A. C., Bennett, F. L., O'Connor, S. J. M., Kwok, M., Fenton, J. A. L., Plummer, M., de Tute, R., Owen, R. G., Richards, S. J., Jack, A. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa075290 · Cited by 613
The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20
Teeling, J. L., Mackus, W. J. M., Wiegman, L. J. J. M., van den Brakel, J. H. N., Beers, S. A., French, R. R., van Meerten, T., Ebeling, S., Vink, T., Slootstra, J. W., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.362 · Cited by 609
Loehrer, P. J. (2008) · Yearbook of Oncology · doi:10.1016/s1040-1741(08)79037-7 · Cited by 602
Brown, J. R., Byrd, J. C., Coutre, S. E., Benson, D. M., Flinn, I. W., Wagner-Johnston, N. D., Spurgeon, S. E., Kahl, B. S., Bello, C., Webb, H. K., et al. (2014) · Blood · doi:10.1182/blood-2013-11-535047 · Cited by 590
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
Wierda, W. G., Kipps, T. J., Mayer, J., Stilgenbauer, S., Williams, C. D., Hellmann, A., Robak, T., Furman, R. R., Hillmen, P., Trneny, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3187 · Cited by 590
Eichhorst, B. F. (2005) · Blood · doi:10.1182/blood-2005-06-2395 · Cited by 588
Rituximab Dose-Escalation Trial in Chronic Lymphocytic Leukemia
O’Brien, S. M., Kantarjian, H., Thomas, D. A., Giles, F. J., Freireich, E. J., Cortes, J., Lerner, S., & Keating, M. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2165 · Cited by 586
Maddocks, K. J., Ruppert, A. S., Lozanski, G., Heerema, N. A., Zhao, W., Abruzzo, L., Lozanski, A., Davis, M., Gordon, A., Smith, L. L., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2014.218 · Cited by 584
The microenvironment in mature B-cell malignancies: a target for new treatment strategies
Burger, J. A., Ghia, P., Rosenwald, A., & Caligaris-Cappio, F. (2009) · Blood · doi:10.1182/blood-2009-06-225326 · Cited by 577
Byrd, J. C. (2003) · Blood · doi:10.1182/blood-2002-04-1258 · Cited by 571
Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia
Hillmen, P., Skotnicki, A. B., Robak, T., Jaksic, B., Dmoszynska, A., Wu, J., Sirard, C., & Mayer, J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.9098 · Cited by 561
Moreno, C., Greil, R., Demirkan, F., Tedeschi, A., Anz, B., Larratt, L., Simkovic, M., Samoilova, O., Novak, J., Ben-Yehuda, D., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30788-5 · Cited by 556
From pathogenesis to treatment of chronic lymphocytic leukaemia
Zenz, T., Mertens, D., Küppers, R., Döhner, H., & Stilgenbauer, S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2764 · Cited by 553
Hoellenriegel, J., Meadows, S. A., Sivina, M., Wierda, W. G., Kantarjian, H., Keating, M. J., Giese, N., O'Brien, S., Yu, A., Miller, L. L., et al. (2011) · Blood · doi:10.1182/blood-2011-05-352492 · Cited by 549
Non-coding recurrent mutations in chronic lymphocytic leukaemia
Puente, X. S., Beà, S., Valdés-Mas, R., Villamor, N., Gutiérrez-Abril, J., Martín-Subero, J. I., Munar, M., Rubio-Pérez, C., Jares, P., Aymerich, M., et al. (2016) · Nature · doi:10.1038/nature18910 · Cited by 546
Osterborg, A., Dyer, M. J., Bunjes, D., Pangalis, G. A., Bastion, Y., Catovsky, D., & Mellstedt, H. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1567 · Cited by 512
Ibrutinib and Venetoclax for First-Line Treatment of CLL
Jain, N., Keating, M., Thompson, P., Ferrajoli, A., Burger, J., Borthakur, G., Takahashi, K., Estrov, Z., Fowler, N., Kadia, T., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1900574 · Cited by 509
Thompson, P. A., Tam, C. S., O’Brien, S. M., Wierda, W. G., Stingo, F., Plunkett, W., Smith, S. C., Kantarjian, H. M., Freireich, E. J., & Keating, M. J. (2016) · Blood · doi:10.1182/blood-2015-09-667675 · Cited by 505
BTK C481S -Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia
Woyach, J. A., Ruppert, A. S., Guinn, D., Lehman, A., Blachly, J. S., Lozanski, A., Heerema, N. A., Zhao, W., Coleman, J., Jones, D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.2282 · Cited by 484
Robak, T., Dmoszynska, A., Solal-Céligny, P., Warzocha, K., Loscertales, J., Catalano, J., Afanasiev, B. V., Larratt, L., Geisler, C. H., Montillo, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.4556 · Cited by 480
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
Fraietta, J. A., Beckwith, K. A., Patel, P. R., Ruella, M., Zheng, Z., Barrett, D. M., Lacey, S. F., Melenhorst, J. J., McGettigan, S. E., Cook, D. R., et al. (2016) · Blood · doi:10.1182/blood-2015-11-679134 · Cited by 474
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
Mato, A. R., Shah, N. N., Jurczak, W., Cheah, C. Y., Pagel, J. M., Woyach, J. A., Fakhri, B., Eyre, T. A., Lamanna, N., Patel, M. R., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00224-5 · Cited by 466
Böttcher, S., Ritgen, M., Fischer, K., Stilgenbauer, S., Busch, R. M., Fingerle-Rowson, G., Fink, A. M., Bühler, A., Zenz, T., Wenger, M. K., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.9348 · Cited by 460
Self-citationMato, A. R., Nabhan, C., Thompson, M. C., Lamanna, N., Brander, D. M., Hill, B., Howlett, C., Skarbnik, A., Cheson, B. D., Zent, C., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.182907 · Cited by 456
Chlorambucil in Indolent Chronic Lymphocytic Leukemia
Dighiero, G., Maloum, K., Desablens, B., Cazin, B., Navarro, M., Leblay, R., Leporrier, M., Jaubert, J., Lepeu, G., Dreyfus, B., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805213382104 · Cited by 447
Knauf, W. U., Lissichkov, T., Aldaoud, A., Liberati, A. M., Loscertales, J., Herbrecht, R., Juliusson, G., Postner, G., Gercheva, L., Goranova-Marinova, V. S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8389 · Cited by 444
Döhner, H., Stilgenbauer, S., James, M. R., Benner, A., Weilguni, T., Bentz, M., Fischer, K., Hunstein, W., & Lichter, P. (1997) · Blood · doi:10.1182/blood.v89.7.2516 · Cited by 439
The French Cooperative Group on CLL, Johnson, S., Smith, A. G., Löffler, H., Ösby, E., Juliusson, G., Emmerich, B., Wyld, P. J., & Hiddemann, W. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91681-5 · Cited by 434
Fischer, K., Cramer, P., Busch, R., Böttcher, S., Bahlo, J., Schubert, J., Pflüger, K. H., Schott, S., Goede, V., Isfort, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.2688 · Cited by 433
Self-citationMoreton, P., Kennedy, B., Lucas, G., Leach, M., Rassam, S. M. B., Haynes, A., Tighe, J., Oscier, D., Fegan, C., Rawstron, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.021 · Cited by 419
Chanan-Khan, A., Cramer, P., Demirkan, F., Fraser, G., Silva, R. S., Grosicki, S., Pristupa, A., Janssens, A., Mayer, J., Bartlett, N. L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00465-9 · Cited by 415
Self-citationChanan-Khan, A., Miller, K. C., Musial, L., Lawrence, D., Padmanabhan, S., Takeshita, K., Porter, C. W., Goodrich, D. W., Bernstein, Z. P., Wallace, P., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.0401 · Cited by 414
Moreau, E., Matutes, E., A’Hern, R., Morilla, A. M., Morilla, R. M., Owusu-Ankomah, K. A., Seon, B. K., & Catovsky, D. (1997) · American Journal of Clinical Pathology · doi:10.1093/ajcp/108.4.378 · Cited by 411
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
Ding, W., LaPlant, B. R., Call, T. G., Parikh, S. A., Leis, J. F., He, R., Shanafelt, T. D., Sinha, S., Le-Rademacher, J., Feldman, A. L., et al. (2017) · Blood · doi:10.1182/blood-2017-02-765685 · Cited by 407
Byrd, J. C. (2005) · Blood · doi:10.1182/blood-2004-03-0796 · Cited by 404
Rawstron, A. C., Villamor, N., Ritgen, M., Böttcher, S., Ghia, P., Zehnder, J. L., Lozanski, G., Colomer, D., Moreno, C., Geuna, M., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404584 · Cited by 403
Self-citationFlinn, I. W., Neuberg, D. S., Grever, M. R., Dewald, G. W., Bennett, J. M., Paietta, E. M., Hussein, M. A., Appelbaum, F. R., Larson, R. A., Moore, D. F., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.0762 · Cited by 402
Lozanski, G., Heerema, N. A., Flinn, I. W., Smith, L., Harbison, J., Webb, J., Moran, M., Lucas, M., Lin, T., Hackbarth, M. L., et al. (2004) · Blood · doi:10.1182/blood-2003-10-3729 · Cited by 398
Landau, D. A., Clement, K., Ziller, M. J., Boyle, P., Fan, J., Gu, H., Stevenson, K., Sougnez, C., Wang, L., Li, S., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.012 · Cited by 394
Leporrier, M., Chevret, S., Cazin, B., Boudjerra, N., Feugier, P., Desablens, B., Rapp, M., Jaubert, J., Autrand, C., Diviné, M., et al. (2001) · Blood · doi:10.1182/blood.v98.8.2319 · Cited by 391
B-cell receptor signaling in chronic lymphocytic leukemia
Stevenson, F. K., Krysov, S., Davies, A. J., Steele, A. J., & Packham, G. (2011) · Blood · doi:10.1182/blood-2011-06-338855 · Cited by 390
Ibrutinib treatment improves T cell number and function in CLL patients
Long, M., Beckwith, K., Do, P., Mundy, B. L., Gordon, A., Lehman, A. M., Maddocks, K. J., Cheney, C., Jones, J. A., Flynn, J. M., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89756 · Cited by 388
Jones, J. A., Mato, A. R., Wierda, W. G., Davids, M. S., Choi, M., Cheson, B. D., Furman, R. R., Lamanna, N., Barr, P. M., Zhou, L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30909-9 · Cited by 383
Fischer, K., Cramer, P., Busch, R., Stilgenbauer, S., Bahlo, J., Schweighofer, C. D., Böttcher, S., Staib, P., Kiehl, M., Eckart, M. J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8061 · Cited by 379
Self-citationGhia, P., Pluta, A., Wach, M., Lysak, D., Kozak, T., Simkovic, M., Kaplan, P., Kraychok, I., Illes, A., de la Serna, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03355 · Cited by 372
The Biology of CD20 and Its Potential as a Target for mAb Therapy
Cragg, M. S., Walshe, C. A., Ivanov, A. O., & Glennie, M. J. (2004) · Current Directions in Autoimmunity · doi:10.1159/000082102 · Cited by 364
Tam, C. S., Trotman, J., Opat, S., Burger, J. A., Cull, G., Gottlieb, D., Harrup, R., Johnston, P. B., Marlton, P., Munoz, J., et al. (2019) · Blood · doi:10.1182/blood.2019001160 · Cited by 361
Wierda, W. G., O'Brien, S., Wang, X., Faderl, S., Ferrajoli, A., Do, K.-A., Cortes, J., Thomas, D., Garcia-Manero, G., Koller, C., et al. (2007) · Blood · doi:10.1182/blood-2005-12-051458 · Cited by 348
Rituximab therapy of patients with B-cell chronic lymphocytic leukemia
Huhn, D. (2001) · Blood · doi:10.1182/blood.v98.5.1326 · Cited by 347
Hillmen, P., Robak, T., Janssens, A., Babu, K. G., Kloczko, J., Grosicki, S., Doubek, M., Panagiotidis, P., Kimby, E., Schuh, A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60027-7 · Cited by 343
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia
Ahn, I. E., Underbayev, C., Albitar, A., Herman, S. E. M., Tian, X., Maric, I., Arthur, D. C., Wake, L., Pittaluga, S., Yuan, C. M., et al. (2017) · Blood · doi:10.1182/blood-2016-06-719294 · Cited by 341
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
Flinn, I. W., Hillmen, P., Montillo, M., Nagy, Z., Illés, Á., Etienne, G., Delgado, J., Kuss, B. J., Tam, C. S., Gasztonyi, Z., et al. (2018) · Blood · doi:10.1182/blood-2018-05-850461 · Cited by 341
Ferrajoli, A., Lee, B.-N., Schlette, E. J., O'Brien, S. M., Gao, H., Wen, S., Wierda, W. G., Estrov, Z., Faderl, S., Cohen, E. N., et al. (2008) · Blood · doi:10.1182/blood-2007-12-130120 · Cited by 337
Al-Sawaf, O., Zhang, C., Tandon, M., Sinha, A., Fink, A.-M., Robrecht, S., Samoylova, O., Liberati, A. M., Pinilla-Ibarz, J., Opat, S., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30443-5 · Cited by 337
Self-citationVenetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
Seymour, J. F., Ma, S., Brander, D. M., Choi, M. Y., Barrientos, J., Davids, M. S., Anderson, M. A., Beaven, A. W., Rosen, S. T., Tam, C. S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30012-8 · Cited by 333
Burger, J. A., Keating, M. J., Wierda, W. G., Hartmann, E., Hoellenriegel, J., Rosin, N. Y., de Weerdt, I., Jeyakumar, G., Ferrajoli, A., Cardenas-Turanzas, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70335-3 · Cited by 332
Chemotherapeutic Options in Chronic Lymphocytic Leukemia: a Meta-analysis of the Randomized Trials
(1999) · Journal of the National Cancer Institute · doi:10.1093/jnci/91.10.861 · Cited by 328
Gauthier, J., Hirayama, A. V., Purushe, J., Hay, K. A., Lymp, J., Li, D. H., Yeung, C. C. S., Sheih, A., Pender, B. S., Hawkins, R. M., et al. (2020) · Blood · doi:10.1182/blood.2019002936 · Cited by 328
Levels of expression of CD19 and CD20 in chronic B cell leukaemias.
Ginaldi, L., De Martinis, M., Matutes, E., Farahat, N., Morilla, R., & Catovsky, D. (1998) · Journal of Clinical Pathology · doi:10.1136/jcp.51.5.364 · Cited by 325
Anti-CD20 Antibody Therapy for B-Cell Lymphomas
Maloney, D. G. (2012) · New England Journal of Medicine · doi:10.1056/nejmct1114348 · Cited by 322
Kikushige, Y., Ishikawa, F., Miyamoto, T., Shima, T., Urata, S., Yoshimoto, G., Mori, Y., Iino, T., Yamauchi, T., Eto, T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.029 · Cited by 317
Kater, A. P., Seymour, J. F., Hillmen, P., Eichhorst, B., Langerak, A. W., Owen, C., Verdugo, M., Wu, J., Punnoose, E. A., Jiang, Y., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01580 · Cited by 309
Rai, K. R., Freter, C. E., Mercier, R. J., Cooper, M. R., Mitchell, B. S., Stadtmauer, E. A., Santábarbara, P., Wacker, B., & Brettman, L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.119 · Cited by 307
Oakes, C. C., Seifert, M., Assenov, Y., Gu, L., Przekopowitz, M., Ruppert, A. S., Wang, Q., Imbusch, C. D., Serva, A., Koser, S. D., et al. (2016) · Nature Genetics · doi:10.1038/ng.3488 · Cited by 307
Dreger, P., Döhner, H., Ritgen, M., Böttcher, S., Busch, R., Dietrich, S., Bunjes, D., Cohen, S., Schubert, J., Hegenbart, U., et al. (2010) · Blood · doi:10.1182/blood-2010-03-275420 · Cited by 305
Self-citationO'Brien, S., Moore, J. O., Boyd, T. E., Larratt, L. M., Skotnicki, A., Koziner, B., Chanan-Khan, A. A., Seymour, J. F., Bociek, R. G., Pavletic, S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.1191 · Cited by 303
Infections in Patients with Chronic Lymphocytic Leukemia Treated with Fludarabine
Anaissie, E. J., Kontoyiannis, D. P., O'Brien, S., Kantarjian, H., Robertson, L., Lerner, S., & Keating, M. J. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-7-199810010-00010 · Cited by 297
Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia
Pflug, N., Bahlo, J., Shanafelt, T. D., Eichhorst, B. F., Bergmann, M. A., Elter, T., Bauer, K., Malchau, G., Rabe, K. G., Stilgenbauer, S., et al. (2014) · Blood · doi:10.1182/blood-2014-02-556399 · Cited by 283
Self-citationIbrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
Hillmen, P., Rawstron, A. C., Brock, K., Muñoz-Vicente, S., Yates, F. J., Bishop, R., Boucher, R., MacDonald, D., Fegan, C., McCaig, A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00894 · Cited by 272
Cardiovascular Toxicities Associated With Ibrutinib
Salem, J.-E., Manouchehri, A., Bretagne, M., Lebrun-Vignes, B., Groarke, J. D., Johnson, D. B., Yang, T., Reddy, N. M., Funck-Brentano, C., Brown, J. R., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.07.056 · Cited by 266
Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia
Gaiti, F., Chaligne, R., Gu, H., Brand, R. M., Kothen-Hill, S., Schulman, R. C., Grigorev, K., Risso, D., Kim, K.-T., Pastore, A., et al. (2019) · Nature · doi:10.1038/s41586-019-1198-z · Cited by 262
Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances
Wen, T., Wang, J., Shi, Y., Qian, H., & Liu, P. (2021) · Leukemia · doi:10.1038/s41375-020-01072-6 · Cited by 262
Hypertension and incident cardiovascular events following ibrutinib initiation
Dickerson, T., Wiczer, T., Waller, A., Philippon, J., Porter, K., Haddad, D., Guha, A., Rogers, K. A., Bhat, S., Byrd, J. C., et al. (2019) · Blood · doi:10.1182/blood.2019000840 · Cited by 260
Flinn, I. W., O’Brien, S., Kahl, B., Patel, M., Oki, Y., Foss, F. F., Porcu, P., Jones, J., Burger, J. A., Jain, N., et al. (2018) · Blood · doi:10.1182/blood-2017-05-786566 · Cited by 252
Faderl, S., Thomas, D. A., O'Brien, S., Garcia-Manero, G., Kantarjian, H. M., Giles, F. J., Koller, C., Ferrajoli, A., Verstovsek, S., Pro, B., et al. (2003) · Blood · doi:10.1182/blood-2002-07-1952 · Cited by 251
Zelenetz, A. D., Barrientos, J. C., Brown, J. R., Coiffier, B., Delgado, J., Egyed, M., Ghia, P., Illés, Á., Jurczak, W., Marlton, P., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30671-4 · Cited by 250
Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1
Pedersen, I. M., Kitada, S., Leoni, L. M., Zapata, J. M., Karras, J. G., Tsukada, N., Kipps, T. J., Choi, Y. S., Bennett, F., & Reed, J. C. (2002) · Blood · doi:10.1182/blood.v100.5.1795.h81702001795_1795_1801 · Cited by 248
CLL), O. B. O. E. (. R. I. O., Rawstron, A. C., Fazi, C., Agathangelidis, A., Villamor, N., Letestu, R., Nomdedeu, J., Palacio, C., Stehlikova, O., Kreuzer, K.-A., et al. (2016) · Leukemia · doi:10.1038/leu.2015.313 · Cited by 248
Self-citationPetlickovski, A., Laurenti, L., Li, X., Marietti, S., Chiusolo, P., Sica, S., Leone, G., & Efremov, D. G. (2005) · Blood · doi:10.1182/blood-2004-07-2669 · Cited by 245
Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction
Kurtz, D. M., Esfahani, M. S., Scherer, F., Soo, J., Jin, M. C., Liu, C. L., Newman, A. M., Dührsen, U., Hüttmann, A., Casasnovas, O., et al. (2019) · Cell · doi:10.1016/j.cell.2019.06.011 · Cited by 236
Self-citationThe risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis
Leong, D. P., Caron, F., Hillis, C., Duan, A., Healey, J. S., Fraser, G., & Siegal, D. (2016) · Blood · doi:10.1182/blood-2016-05-712828 · Cited by 233
Mato, A. R., Hill, B. T., Lamanna, N., Barr, P. M., Ujjani, C. S., Brander, D. M., Howlett, C., Skarbnik, A. P., Cheson, B. D., Zent, C. S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx031 · Cited by 229
Tsukada, N., Burger, J. A., Zvaifler, N. J., & Kipps, T. J. (2002) · Blood · doi:10.1182/blood.v99.3.1030 · Cited by 226
Sharman, J. P., Coutre, S. E., Furman, R. R., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01460 · Cited by 224
Self-citationRobak, T., Błoński, J. Z., Kasznicki, M., Błasińska-Morawiec, M., Krykowski, E., Dmoszyńska, A., Mrugala-Śpiewak, H., Skotnicki, A. B., Nowak, W., Konopka, L., et al. (2000) · PubMed · doi:10.1182/blood.v96.8.2723.h8002723_2723_2729 · Cited by 218
Ibrutinib antagonizes rituximab-dependent NK cell–mediated cytotoxicity
Kohrt, H. E., Sagiv-Barfi, I., Rafiq, S., Herman, S. E. M., Butchar, J. P., Cheney, C., Zhang, X., Buggy, J. J., Muthusamy, N., Levy, R., et al. (2014) · Blood · doi:10.1182/blood-2014-01-547869 · Cited by 217
Stilgenbauer, S., & Döhner, H. (2002) · New England Journal of Medicine · doi:10.1056/nejm200208083470619 · Cited by 216
Elter, T., Borchmann, P., Schulz, H., Reiser, M., Trelle, S., Schnell, R., Jensen, M., Staib, P., Schinköthe, T., Stützer, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.9950 · Cited by 209
Self-citationSchulz, H. (2002) · Blood · doi:10.1182/blood-2002-03-0972 · Cited by 204
Jones, J. A., Robak, T., Brown, J. R., Awan, F. T., Badoux, X., Coutre, S., Loscertales, J., Taylor, K., Vandenberghe, E., Wach, M., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30019-4 · Cited by 202
Dreger, P., Schetelig, J., Andersen, N., Corradini, P., van Gelder, M., Gribben, J., Kimby, E., Michallet, M., Moreno, C., Stilgenbauer, S., et al. (2014) · Blood · doi:10.1182/blood-2014-07-586826 · Cited by 199
Di Gaetano, N., Xiao, Y., Erba, E., Bassan, R., Rambaldi, A., Golay, J., & Introna, M. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03014.x · Cited by 198
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
Herling, C. D., Abedpour, N., Weiss, J., Schmitt, A., Jachimowicz, R. D., Merkel, O., Cartolano, M., Oberbeck, S., Mayer, P., Berg, V., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03170-7 · Cited by 198
Self-citationThe reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia
Beekman, R., Chapaprieta, V., Russiñol, N., Vilarrasa-Blasi, R., Verdaguer-Dot, N., Martens, J. H. A., Duran-Ferrer, M., Kulis, M., Serra, F., Javierre, B. M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0028-4 · Cited by 195
Kennedy, B., Rawstron, A., Carter, C., Ryan, M., Speed, K., Lucas, G., & Hillmen, P. (2002) · Blood · doi:10.1182/blood.v99.6.2245 · Cited by 186
Awan, F. T., Schuh, A., Brown, J. R., Furman, R. R., Pagel, J. M., Hillmen, P., Stephens, D. M., Woyach, J., Bibikova, E., Charuworn, P., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018030007 · Cited by 185
The triterpenoid CDDO induces apoptosis in refractory CLL B cells
Pedersen, I. M., Kitada, S., Schimmer, A., Kim, Y., Zapata, J. M., Charboneau, L., Rassenti, L., Andreeff, M., Bennett, F., Sporn, M. B., et al. (2002) · Blood · doi:10.1182/blood-2002-04-1174 · Cited by 183
Bosch, F., Ferrer, A., López‐Guillermo, A., Giné, E., Bellosillo, B., Villamor, N., Colomer, D., Cobo, F., Perales, M., Esteve, J., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03959.x · Cited by 181
Frey, N. V., Gill, S., Hexner, E. O., Schuster, S., Nasta, S., Loren, A., Svoboda, J., Stadtmauer, E., Landsburg, D. J., Mato, A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03237 · Cited by 179
Byrd, J. C., Wierda, W. G., Schuh, A., Devereux, S., Chaves, J. M., Brown, J. R., Hillmen, P., Martin, P., Awan, F. T., Stephens, D. M., et al. (2020) · Blood · doi:10.1182/blood.2018884940 · Cited by 178
Kovacs, G., Robrecht, S., Fink, A. M., Bahlo, J., Cramer, P., von Tresckow, J., Maurer, C., Langerbeins, P., Fingerle-Rowson, G., Ritgen, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1305 · Cited by 175
Self-citationPrognostic factors in chronic lymphocytic leukemia—what do we need to know?
Cramer, P., & Hallek, M. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.167 · Cited by 173
Self-citationZenz, T., Vollmer, D., Trbusek, M., Smardova, J., Benner, A., Soussi, T., Helfrich, H., Heuberger, M., Hoth, P., Fuge, M., et al. (2010) · Leukemia · doi:10.1038/leu.2010.208 · Cited by 169
Self-citationChen, Q., Jain, N., Ayer, T., Wierda, W. G., Flowers, C. R., O’Brien, S. M., Keating, M. J., Kantarjian, H. M., & Chhatwal, J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.2856 · Cited by 169
O'Brien, S., Moore, J. O., Boyd, T. E., Larratt, L. M., Skotnicki, A. B., Koziner, B., Chanan-Khan, A. A., Seymour, J. F., Gribben, J., Itri, L. M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.5748 · Cited by 167
Badoux, X. C., Keating, M. J., Wen, S., Wierda, W. G., O'Brien, S. M., Faderl, S., Sargent, R., Burger, J. A., & Ferrajoli, A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8623 · Cited by 158
Cartron, G., de Guibert, S., Dilhuydy, M., Morschhauser, F., Leblond, V., Dupuis, J., Mahé, B., Bouabdallah, R., Lei, G., Wenger, M., et al. (2014) · Blood · doi:10.1182/blood-2014-07-586610 · Cited by 157
Self-citationFludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies.
Plunkett, W., Gandhi, V., Huang, P., et al. (1993) · PubMed · Cited by 150
Patz, M., Isaeva, P., Forcob, N., Müller, B., Frenzel, L. P., Wendtner, C., Klein, C., Umaña, P., Hallek, M. J., & Krause, G. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08428.x · Cited by 149
Self-citationInternational prognostic score for asymptomatic early-stage chronic lymphocytic leukemia
Condoluci, A., di Bergamo, L. T., Langerbeins, P., Hoechstetter, M. A., Herling, C., Paoli, L. D., Delgado, J., Rabe, K. G., Gentile, M., Doubek, M., et al. (2020) · Blood · doi:10.1182/blood.2019003453 · Cited by 146
Self-citationNovel CD20 monoclonal antibodies for lymphoma therapy
Cang, S., Mukhi, N., Wang, K., & Liu, D. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-64 · Cited by 140
Jaglowski, S. M., Jones, J. A., Nagar, V., Flynn, J. M., Andritsos, L. A., Maddocks, K. J., Woyach, J. A., Blum, K. A., Grever, M. R., Smucker, K. A., et al. (2015) · Blood · doi:10.1182/blood-2014-12-617522 · Cited by 138
Minimal residual disease is an independent predictor for 10-year survival in CLL
Kwok, M., Rawstron, A. C., Varghese, A. M., Evans, P., O’Connor, S. J. M., Doughty, C., Newton, D. J., Moreton, P., & Hillmen, P. (2016) · Blood · doi:10.1182/blood-2016-05-714162 · Cited by 137
Xu, W., Yang, S., Zhou, K., Pan, L., Li, Z., Zhou, J., Gao, S., Zhou, D., Hu, J., Feng, R., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00884-4 · Cited by 129
Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations
Ahn, I. E., Tian, X., & Wiestner, A. U. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2005943 · Cited by 123
Venetoclax and obinutuzumab in chronic lymphocytic leukemia
Fischer, K., Al‐Sawaf, O., Fink, A., Dixon, M., Bahlo, J., Warburton, S., Kipps, T. J., Weinkove, R., Robinson, S., Seiler, T., et al. (2017) · Blood · doi:10.1182/blood-2017-01-761973 · Cited by 119
Self-citationFraser, G. A. M., Cramer, P., Demırkan, F., da Silva, R. S. A., Grosicki, S., Pristupa, A. S., Janssens, A. M., Mayer, J., Bartlett, N. L., Dilhuydy, M. S., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0276-9 · Cited by 119
Self-citationDavids, M. S., Kim, H. T., Nicotra, A., Savell, A., Francoeur, K., Hellman, J. M., Bazemore, J., Miskin, H. P., Sportelli, P., Stampleman, L. V., et al. (2018) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30196-0 · Cited by 117
Herman, S. E. M., Mustafa, R. Z., Jones, J. E., Wong, D. H., Farooqui, M. Z. H., & Wiestner, A. U. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0781 · Cited by 116
Rogers, K. A., Thompson, P. A., Allan, J. N., Coleman, M., Sharman, J. P., Cheson, B. D., Jones, D., Izumi, R. E., Frigault, M. M., Quah, C. S., et al. (2021) · Haematologica · doi:10.3324/haematol.2020.272500 · Cited by 114
Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies
Hallek, M. J. (2013) · Blood · doi:10.1182/blood-2013-05-498287 · Cited by 113
Self-citationCramer, P., von Tresckow, J., Bahlo, J., Robrecht, S., Langerbeins, P., Al‐Sawaf, O., Engelke, A., Fink, A., Fischer, K., Tausch, E., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30414-5 · Cited by 113
Self-citationReinart, N., Nguyen, P., Bouças, J., Rosen, N., Kvasnicka, H. M., Heukamp, L. C., Rudolph, C., Ristovska, V., Velmans, T., Mueller, C., et al. (2012) · Blood · doi:10.1182/blood-2012-05-431452 · Cited by 109
Self-citationRogers, K. A., Huang, Y., Ruppert, A. S., Abruzzo, L. V., Andersen, B. L., Awan, F. T., Bhat, S. A., Dean, A., Lucas, M. S., Banks, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00491 · Cited by 109
Morice, W. G., Kurtin, P. J., Hodnefield, J. M., Shanafelt, T. D., Hoyer, J. D., Remstein, E. D., & Hanson, C. A. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.7.776 · Cited by 108
Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia
Fiorcari, S., Maffei, R., Audrito, V., Martinelli, S., ten Hacken, E., Zucchini, P., Grisendi, G., Potenza, L., Luppi, M., Burger, J. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11782 · Cited by 108
Ahn, I. E., Tian, X., Ipe, D., Cheng, M. L., Albitar, M. X., Tsao, L. C., Zhang, L., Ma, W., Herman, S. E. M., Gaglione, E. M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00979 · Cited by 108
Rogers, K. A., Huang, Y., Ruppert, A. S., Awan, F. T., Heerema, N. A., Hoffman, C., Lozanski, G., Maddocks, K. J., Moran, M. E., Reid, M. A., et al. (2018) · Blood · doi:10.1182/blood-2018-05-853564 · Cited by 107
Acalabrutinib in treatment-naive chronic lymphocytic leukemia
Byrd, J. C., Woyach, J. A., Furman, R. R., Martin, P., O'Brien, S. M., Brown, J. R., Stephens, D. M., Barrientos, J. C., Devereux, S., Hillmen, P., et al. (2021) · Blood · doi:10.1182/blood.2020009617 · Cited by 102
Leprêtre, S., Aurran, T., Mahé, B., Cazin, B., Tournilhac, O., Maisonneuve, H., Casasnovas, O., Delmer, A. J., Leblond, V., Royer, B., et al. (2012) · Blood · doi:10.1182/blood-2011-07-365437 · Cited by 98
Elter, T., Gercheva, L., Pylylpenko, H., Robak, T., Jaksic, B. S., Rekhtman, G. B., Kyrcz‐Krzemień, S., Vatutin, M. T., Wu, J., Sirard, C. A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70242-x · Cited by 92
Self-citationNguyen, P., Fedorchenko, O., Rosen, N., Koch, M., Barthel, R., Winarski, T., Florin, A., Wunderlich, F. T., Reinart, N., & Hallek, M. J. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.007 · Cited by 90
Self-citationWoyach, J. A., Blachly, J. S., Rogers, K. A., Bhat, S. A., Jianfar, M., Lozanski, G., Weiss, D. M., Andersen, B. L., Gulrajani, M., Frigault, M. M., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1130 · Cited by 83
Abdel-Qadir, H. M., Sabrie, N., Leong, D. P., Pang, A., Austin, P. C., Prica, A. A., Nanthakumar, K., Arguelles, O. C., Lee, D. S., & Thavendiranathan, P. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00693 · Cited by 83
Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics
Sher, T., Miller, K. C., Lawrence, D. D., Whitworth, A., Hernandez‐Ilizaliturri, F. J., Czuczman, M. S., Miller, A., Lawrence, W., Bilgrami, S. A. A., Sood, R., et al. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190903406806 · Cited by 82
Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia
Strati, P., Keating, M. J., Wierda, W. G., et al. (2013) · Blood · doi:10.1182/blood-2013-04-495341 · Cited by 79
Discovery of Candidate DNA Methylation Cancer Driver Genes
Pan, H., Renaud, L., Chaligné, R., Bloehdorn, J., Tausch, E., Mertens, D., Fink, A. M., Fischer, K., Zhang, C., Betel, D., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1334 · Cited by 73
Self-citationBorge, M., Almejún, M. B., Podaza, E., Colado, A., Grecco, H. F., Cabrejo, M., Bezares, R. F., Giordano, M., & Gamberale, R. (2015) · Haematologica · doi:10.3324/haematol.2014.119669 · Cited by 72
Maffei, R., Fiorcari, S., Martinelli, S., Potenza, L., Luppi, M., & Marasca, R. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0157-x · Cited by 63
Tumor Lysis Syndrome/Tumor Flare Reaction in Lenalidomide-Treated Chronic Lymphocytic Leukemia
Parseval, L. M., Weiss, L., DeLap, R. J., Knight, R., & Zeldis, J. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2141 · Cited by 60
Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia
Wiestner, A. U. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.88.3801172 · Cited by 59
Seymour, J. F., Davids, M. S., Pagel, J. M., Kahl, B. S., Wierda, W. G., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Huang, D. C. S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.7015 · Cited by 58
Gauthier, J., Hirayama, A. V. V., Hay, K. A., Li, D., Lymp, J. F., Sheih, A., Purushe, J., Pender, B. S., Hawkins, R. M., Vakil, A., et al. (2018) · Blood · doi:10.1182/blood-2018-99-111061 · Cited by 58
Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia
Bauer, K. H., Rancea, M., Roloff, V., Elter, T., Hallek, M. J., Engert, A., & Skoetz, N. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008079.pub2 · Cited by 57
Self-citationJain, P., Keating, M. J., Wierda, W. G., Sivina, M., Thompson, P. A., Ferrajoli, A., Estrov, Z. E., Kantarjian, H. M., O'Brien, S. M., & Burger, J. A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1948 · Cited by 57
Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia
Seiffert, M., Dietrich, S., Jethwa, A., Glimm, H., Lichter, P., & Zenz, T. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.631638 · Cited by 56
Rituximab for the Treatment of Non-Hodgkinʼs Lymphoma and Chronic Lymphocytic Leukaemia
Hagemeister, F. C. (2010) · Drugs · doi:10.2165/11532180-000000000-00000 · Cited by 51
Purine Antagonists for Chronic Lymphocytic Leukaemia
Steurer, M., Pall, G., Richards, S. M., Schwarzer, G., Bohlius, J., & Greil, R. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004270.pub2 · Cited by 50
Bassig, B. A., Au, W., Mang, O., Ngan, R. K. C., Morton, L. M., Ip, D., Hu, W., Zheng, T., Seow, W. J., Xu, J., et al. (2016) · Cancer Epidemiology · doi:10.1016/j.canep.2016.02.007 · Cited by 50
von Tresckow, J., Cramer, P., Bahlo, J., Robrecht, S., Langerbeins, P., Fink, A., Al‐Sawaf, O., Illmer, T., Klaproth, H., Estenfelder, S., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0313-8 · Cited by 42
Self-citationNew roles for B cell receptor associated kinases: when the B cell is not the target
Nguyen, P., Niesen, E., & Hallek, M. J. (2019) · Leukemia · doi:10.1038/s41375-018-0366-8 · Cited by 41
Self-citationGalletti, G., Caligaris‐Cappio, F., & Bertilaccio, M. T. S. (2016) · Leukemia · doi:10.1038/leu.2016.261 · Cited by 40
Cited by
Alaggio, R., Amador, C., Anagnostopoulos, I., Attygalle, A. D., Araujo, I. B. D. O., Berti, E., Bhagat, G., Borges, A. M., Boyer, D., Calaminici, M., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01620-2 · Cited by 4,004
Consequences of genetic variants in miRNA genes
Machowska, M., Galka-Marciniak, P., & Kozlowski, P. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.11.036 · Cited by 40
Integrin Signaling Shaping BTK-Inhibitor Resistance
Polcik, L., Dannewitz Prosseda, S., Pozzo, F., Zucchetto, A., Gattei, V., & Hartmann, T. N. (2022) · Cells · doi:10.3390/cells11142235 · Cited by 15
Metadata
- Authors
- Hallek, M., & Al‐Sawaf, O.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2021-11-24
- Volume
- 96
- Issue
- 12
- Pages
- 1679-1705
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W3204288598
- Cited by
- 393
- References
- 210
- FWCI
- 28.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.